| Literature DB >> 16020511 |
Heddy Zola1, Bernadette Swart, Ian Nicholson, Bent Aasted, Armand Bensussan, Laurence Boumsell, Chris Buckley, Georgina Clark, Karel Drbal, Pablo Engel, Derek Hart, Václav Horejsí, Clare Isacke, Peter Macardle, Fabio Malavasi, David Mason, Daniel Olive, Armin Saalmueller, Stuart F Schlossman, Reinhard Schwartz-Albiez, Paul Simmons, Thomas F Tedder, Mariagrazia Uguccioni, Hilary Warren.
Abstract
The immune system works through leukocytes interacting with each other, with other cells, with tissue matrices, with infectious agents, and with other antigens. These interactions are mediated by cell-surface glycoproteins and glycolipids. Antibodies against these leukocyte molecules have provided powerful tools for analysis of their structure, function, and distribution. Antibodies have been used widely in hematology, immunology, and pathology, and in research, diagnosis, and therapy. The associated CD nomenclature is commonly used when referring to leukocyte surface molecules and antibodies against them. It provides an essential classification for diagnostic and therapeutic purposes. The most recent (8th) Workshop and Conference on Human Leukocyte Differentiation Antigens (HLDA), held in Adelaide, Australia, in December 2004, allocated 95 new CD designations and made radical changes to its aims and future operational strategy in order to maintain its relevance to modern human biology and clinical practice.Entities:
Mesh:
Substances:
Year: 2005 PMID: 16020511 DOI: 10.1182/blood-2005-03-1338
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113